Russia's Pharmsynthez plans IPO to expand business
This article was originally published in Scrip
St Petersburg-based Pharmsynthez has set an indicative price range of between Rb20.6 ($0.67) and Rb27.7 per ordinary share for its initial public offering on the innovation and investments market on the Moscow Interbank Currency Exchange (MICEX) at the end of November. The IPO will comprise around 23 million ordinary shares representing around one third of its nominal capital.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.